Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NBTX) has issued a standard regulatory filing regarding its voting rights and share capital in compliance with French regulatory requirements. The announcement was made in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the French Financial Markets Authority regulations.

The company's shares are listed on both Euronext Paris (Compartment B) and Nasdaq under the ticker symbol NBTX. The company's ISIN code is FR0011341205.

Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in two major investor conferences in early 2025.

The company will participate in fireside chats at the following events:

• Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 1pm ET in New York, featuring CFO Bart van Rhijn
• Leerink Global Healthcare Conference on March 12, 2025, at 10:40pm ET in Miami, featuring CEO Laurent Levy and CFO Bart van Rhijn

Both fireside chats will be webcast live through the company's website's Investors section, with replays available after the events.

Nanobiotix announced the dosing of the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating JNJ-1900 (NBTXR3) for treating Stage 3 unresectable non-small cell lung cancer. The study will assess patients receiving standard chemoradiation followed by consolidation durvalumab.

The trial (NCT06667908) is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. JNJ-1900 is a potential first-in-class radioenhancer designed to address unmet needs in radiotherapy patients. This development follows the NANORAY-312 trial path for potential registration in head and neck cancer.

Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.

Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.

The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.

Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of November 30, 2024. The company has 47,426,851 shares outstanding, with 49,202,229 theoretical voting rights and 49,180,111 exercisable voting rights. Nanobiotix, founded in 2003 and headquartered in Paris, is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients. The study showed encouraging results with 23 months median Overall Survival from diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson.

The treatment was well-tolerated, and investigators concluded the favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial. The FDA approved a protocol amendment to launch a new cohort studying NBTXR3 combined with standard-of-care concurrent chemotherapy, with recruitment currently ongoing. Full data presentation is expected at a medical congress in first half of 2025.

Nanobiotix has released its monthly report on voting rights and share capital as of October 31, 2024. The company reported 47,426,851 shares outstanding, with 49,201,086 theoretical voting rights and 49,178,968 exercisable voting rights. The company's shares are listed on both Euronext Paris and Nasdaq under the ticker symbol NBTX.